These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24781224)

  • 1. [The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(3):34-40. PubMed ID: 24781224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
    Schlagenhauf F; Dinges M; Beck A; Wüstenberg T; Friedel E; Dembler T; Sarkar R; Wrase J; Gallinat J; Juckel G; Heinz A
    Schizophr Res; 2010 May; 118(1-3):189-200. PubMed ID: 20189356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
    J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
    Lin SK; Chen CK
    J Clin Psychiatry; 2006 Aug; 67(8):1307. PubMed ID: 16965214
    [No Abstract]   [Full Text] [Related]  

  • 15. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole: pharmacology, efficacy, safety and tolerability.
    Kinghorn WA; McEvoy JP
    Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
    Schorr SG; Slooff CJ; Postema R; Van Oven W; Schilthuis M; Bruggeman R; Taxis K
    Acta Psychiatr Scand; 2008 Sep; 118(3):246-50. PubMed ID: 18699955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.